Mark Gannott

I operate across life sciences and emerging therapeutics as a venture investor, fractional CFO, and strategic operator, focused on healthcare leverage: the small number of interventions that drive outsized clinical and economic outcomes. As a Venture Partner, I invest in and support companies across diagnostics, medical devices, care delivery, and biologically driven platforms, particularly where value is obscured by underdiagnosis, adoption friction, or misunderstood economics. I’m most active at the transition point between technical validation and real-world scale, where reimbursement, clinical adoption, and execution risk begin to dominate outcomes. This is where disciplined underwriting matters most. In parallel with investing, I work directly with founders before and between rounds as a fractional CFO and operator, helping design and run the financial systems that support scale: capital planning, runway management, operating models, data rooms, and milestone-driven financing strategy. This hands-on CFO work directly informs how I underwrite risk as an investor and how I support companies through critical inflection points. I hold an Adjunct Fellowship at the NICM Health Research Institute (Western Sydney University), where my work focuses on applied health economics and outcomes research for chronic pelvic conditions. My academic contributions include national cost-of-illness studies, burden frameworks, and access strategies for diagnostics and condition-specific care systems. This research grounds my investment and operating work in real-world disease economics. My core wedge is health economics. I translate scientific and clinical complexity into structured narratives investors can underwrite, using disease burden, diagnostic delay, utilization shifts, and payer dynamics to define unit economics and support defensible capital forecasts. This lens allows me to selectively underwrite technically sophisticated science where I have asymmetric domain understanding, pairing scientific diligence with adoption and economic realism. Alongside founder and portfolio work, I advise venture funds, private equity, and venture studios on diligence frameworks, LP narrative, and strategic modeling in technically complex healthcare categories. Throughout my work, I draw on early economics training focused on mental health, emerging therapeutics, and systems of underdiagnosis. The throughline is making invisible risk legible—so capital can be deployed with precision rather than approximation. Precision isn’t optional when lives and outcomes are at stake.